Dosing and Administration
Moving needle injection technique
The technique for injecting NOCITA® (bupivacaine liposome injectable suspension) into a surgical site differs slightly from using traditional bupivacaine formulation, because the liposomes themselves do not readily diffuse from where they are deposited.
Therefore, a moving-needle injection technique is used to inject the suspension into all tissue layers of the surgical field. As bupivacaine is gradually released from individual liposomes, it will diffuse locally into the surrounding tissues.
NOCITA is for single-dose administration following cranial cruciate ligament surgery.
A dose of 5.3 mg/kg (0.4 mL/kg) can be given by tissue infiltration injection during surgery for post-operative analgesia following cranial cruciate ligament surgery. A single dose may provide up to 72 hours of pain control.
NOCITA Administration Demonstration
*Cranial cruciate ligament
IMPORTANT SAFETY INFORMATION: NOCITA® (bupivacaine liposome injectable suspension) is for use in dogs only. Do not use in dogs younger than 5 months of age, dogs used for breeding, or in pregnant or lactating dogs. Do not administer by intravenous or intra-arterial injection. Adverse reactions in dogs may include discharge from incision, incisional inflammation and vomiting. Avoid concurrent use with bupivacaine HCl, lidocaine or other amide local anesthetics. Please see the full Prescribing Information for more detail.
NOCITA is now available.
“We began using Nocita on patients undergoing cranial cruciate ligament stabilization surgeries and have been very pleased with the results. The product is intuitive to use and we have observed nothing but positive effects for our patients post-operatively. Specifically, these patients appear to bear more significant weight immediately post-op than usually expected, require very little rescue analgesia, and are willing to eat early in the recovery period which has allowed easy transition to oral medications. Nocita has quickly become standard protocol for analgesia on our cruciate ligament stabilization procedures.”Veterinary Surgeon
Other therapeutics from Aratana
ENTYCE® (capromorelin oral solution)
provides appetite stimulation.
Inappetence in dogs is a serious problem. Recently-FDA-approved ENTYCE® provides safe, effective appetite stimulation.
IMPORTANT SAFETY INFORMATION: ENTYCE® (capromorelin oral solution) is for use in dogs only. Do not use in breeding, pregnant or lactating dogs. Use with caution in dogs with hepatic dysfunction or renal insufficiency. Adverse reactions in dogs may include diarrhea, vomiting, polydipsia, and hypersalivation. Should not be used in dogs that have a hypersensitivity to capromorelin. Please see the full Prescribing Information for more detail.